PRODUCT_WITH_CATEGORY
Products
Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. Daiichi Sankyo, Inc. medicines approved in the U.S. are outlined below and include therapies for metastatic breast, lung and gastric cancer, tenosynovial giant cell tumor, thrombosis, stroke risk reduction, and IV iron therapy.
Click to view Daiichi Sankyo Products available in other countries:
WorldwideU.S. Products
ENHERTU®
(fam-trastuzumab deruxtecan-nxki)
See full prescribing Information, including boxed warnings and medication guide.
SAVAYSA®
(edoxaban) tablets
See full prescribing Information, including boxed warnings and medication guide.
TURALIO®
(Pexidartinib)
See full prescribing Information, including boxed warning regarding liver toxicity and medication guide.
Have a question about a product?
Please call the Daiichi Sankyo Contact Center at 1-877-4 DS-PROD
(1-877-437-7763) if you have a question about any of our products or to report
any adverse reactions to our products. To report negative side effects of
prescription drugs to the FDA, visit www.fda.gov/medwatch